0 3 min 8 mths

[ad_1]

While the best-selling mRNA vaccines are still pending full approval by the FDA, the US is already working to give the “super soldiers of tomorrow” a head start by developing a “universal” COVID vaccine that will be effective against all future variants target. The US Army will complete initial clinical trials with the new vaccine in the coming weeks.

The new vaccine, called SpFN (Spike Ferritin Nanoparticle), has reportedly shown promise in trials with non-human primates, and the first results from human trials are expected in December, a press release said Walter Reed Army Institute of Research der US-Armee.

The vaccine is intended as a starting point for a forward-looking “pan-SARS” strategy to tackle the current pandemic and serve as the first line of defense against worrying variants and similar viruses that may emerge in the future.

The accelerated occurrence of human coronaviruses in the last two decades and the occurrence of SARS-CoV-2 variants, including most recently Omikron, underscore the continuing need for preventive vaccines of the next generation that offer comprehensive protection against coronavirus diseases, “said Dr . Kayvon Modjarrad, director of the emerging infectious diseases division at WRAIR, co-inventor of the vaccine and head of the US Army’s SpFN project. “Our strategy was to develop a ‘pan-coronavirus’ vaccine technology that could potentially provide safe, effective and permanent protection against multiple coronavirus strains and species.

SpFN started in Phase 1 human trials in April 2021. Early analyzes, which should be completed this month, will provide information on whether the efficacy and breadth of the SpFN vaccine demonstrated in preclinical trials can be transferred to humans.

The data will also help researchers compare the immunity profile of SpFN with that of other COVID vaccines that are already approved for emergency use.

This vaccine stands out in the COVID-19 vaccine landscape, ”Modjarrad said. “The repeated and orderly depiction of the coronavirus spike protein on a nanoparticle with multiple faces could stimulate immunity in such a way that it leads to a significantly broader protection.

We can imagine that we will hear more about this very soon.

[ad_2]

Source link

Leave a Reply

Your email address will not be published.